Oral Semaglutide Demonstrated Significant Reduction in Blood S...
ORLANDO, Florida, June 24, 2018 /PRNewswire-AsiaNet/-- Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, according to findings from the PIONEER 1 phase 3a trial. The trial eval...